Hamoda Haitham, Ashok Premila W, Flett Gillian M M, Templeton Allan
Department of Obstetrics and Gynaecology, University of Aberdeen, Aberdeen, United Kingdom.
Am J Obstet Gynecol. 2004 Jan;190(1):55-9. doi: 10.1016/j.ajog.2003.08.025.
The purpose of this study was to compare the effectiveness of the sublingual and vaginal administration of misoprostol for cervical priming before surgical termination of pregnancy.
In a randomized controlled trial, 74 primigravid women who were undergoing surgical abortion were assigned randomly to receive misoprostol (400 microg) sublingually or vaginally.
There was no statistically significant difference in the cumulative force that was required to dilate the cervix to 9 mm, for baseline cervical dilatation, for priming to abortion interval, for operating time, or for intraoperative blood loss between the two groups. Women in the sublingual group had more nausea (P=.008), vomiting (P=.01), diarrhea (P=.01), and unpleasant mouth taste (P=.0001) compared with the women in the vaginal group. In the sublingual group, 65% of women were satisfied with the route of misoprostol administration compared with 78% in the vaginal group (P=.11). Most of the staff members (84%) said that they would recommend the sublingual administration of misoprostol (P=.0001).
The sublingual administration of misoprostol is an effective alternative to vaginal administration for cervical priming before surgical abortion; despite a higher incidence of side effects, there was high patient and staff acceptability.
本研究旨在比较米索前列醇舌下含服与阴道给药在手术终止妊娠前宫颈准备中的有效性。
在一项随机对照试验中,74例接受手术流产的初孕妇被随机分配接受米索前列醇(400微克)舌下含服或阴道给药。
两组在将宫颈扩张至9毫米所需的累积力量、基线宫颈扩张程度、准备至流产间隔时间、手术时间或术中失血量方面无统计学显著差异。与阴道给药组的女性相比,舌下含服组的女性恶心(P = 0.008)、呕吐(P = 0.01)、腹泻(P = 0.01)和口腔异味(P = 0.0001)的发生率更高。在舌下含服组中,65%的女性对米索前列醇给药途径满意,而阴道给药组为78%(P = 0.11)。大多数工作人员(84%)表示他们会推荐米索前列醇舌下含服(P = 0.0001)。
米索前列醇舌下含服是手术流产前宫颈准备中阴道给药的有效替代方法;尽管副作用发生率较高,但患者和工作人员的接受度较高。